Neuronetics

Neuronetics Debt

The Debt of Neuronetics (STIM) as of Oct 9, 2026 is 90.30 M USD. In the previous year, Debt was 82.63 M USD — a change of 9.29% (higher).

Debt

90.30 MUSD

YoY

9.29%

Last updated:

In 2025, Neuronetics's total debt was 90.30 M USD, a 9.29% change from the 82.63 M USD total debt recorded in the previous year.

The Neuronetics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
30.40 M USD
Jan 1, 2019
34.33 M USD
Jan 1, 2020
38.34 M USD
Jan 1, 2021
39.54 M USD
Jan 1, 2022
39.75 M USD
Jan 1, 2023
62.47 M USD
Jan 1, 2024
82.63 M USD
Jan 1, 2025
90.30 M USD
The Neuronetics Debt history
YEARDebtYoY
90.30 MUSD+9.29%
82.63 MUSD+32.26%
62.47 MUSD+57.19%
39.75 MUSD+0.51%
39.54 MUSD+3.15%
38.34 MUSD+11.68%
34.33 MUSD+12.93%
30.40 MUSD-48.99%
59.59 MUSD+189.31%
20.60 MUSD—
Access this data via the Eulerpool API

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

Debt Details

Understanding Neuronetics's Debt Structure

Neuronetics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Neuronetics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Neuronetics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Neuronetics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Neuronetics stock

Debt of Neuronetics is 90.30 M USD in 2025.

Debt of Neuronetics changed from 82.63 M USD to 90.30 M USD, representing a 9.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Neuronetics since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Neuronetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Neuronetics

All Key Metrics — Neuronetics